Oxtellar XR and Trokendi XR jointly generated sales of $38.7 million in the first half of 2014. We believe both products should pick up sales significantly in order to meet the revenue guidance for 2014. Herein, it is important to note that the market for epilepsy products is competitive with the presence of products like Potiga, Vimpat, Banzel and Aptiom.